Singapore

Population 2018: 5.8 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>2.7 (2.3–3.1)</td>
<td>47 (40–54)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.035 (0.022–0.05)</td>
<td>0.6 (0.39–0.87)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.046 (0.027–0.071)</td>
<td>0.81 (0.47–1.2)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.051 (0.037–0.067)</td>
<td>0.89 (0.64–1.2)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>&lt;0.01 (&lt;0.01–&lt;0.01)</td>
<td>0.09 (0.05–0.15)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases: 1.6%
- Previously treated cases: 3.5% (0.73–9.9)

TB case notifications, 2018
- Total new and relapse: 2,331
  - % tested with rapid diagnostics at time of diagnosis: 60%
  - % with known HIV status: 89%
  - % pulmonary: 85%
  - % bacteriologically confirmed**:<sup>**</sup> 62%
  - % children aged 0–14 years: <1%
  - % women: 39%
  - % men: 61%
- Total cases notified: 2,334

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
- TB patients facing catastrophic total costs: 2% (1–3)
- TB/HIV care in new and relapse TB patients, 2018: Number (%)
  - Patients with known HIV status who are HIV-positive: 27 1%
    - on antiretroviral therapy

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**:<sup>**</sup> 98%
  - % with known HIV status: 98%
Laboratory-confirmed cases**:<sup>**</sup>
- MDR/RR-TB: 22, XDR-TB: 0
- MDR/RR-TB: 15, XDR-TB: 0
- MDR/RR-TB cases tested for resistance to second-line drugs: 17

Treatment success rate and cohort size
- New and relapse cases registered in 2017: 79% 2,300
- Previously treated cases, excluding relapse, registered in 2017: 100% 4
- HIV-positive TB cases registered in 2017: 81% 31
- MDR/RR-TB cases started on second-line treatment in 2016: 26% 19
- XDR-TB cases started on second-line treatment in 2016: 0

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 0%
- % of children (aged <5) household contacts of bacteriologically-confirmed: 100%
- TB cases on preventive treatment

TB financing, 2019
- National TB budget (US$ millions)

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*<sup>**</sup> Calculated for pulmonary cases only
** Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Generated: 2019-10-18 Data: www.who.int/tb/data